SEARCH:   Advanced

Blood, 1 August 2006, Vol. 108, No. 3, pp. 870-877. Prepublished online as a Blood First Edition Paper on April 6, 2006; DOI 10.1182/blood-2005-08-009357. This Article Full Text Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2005-08-009357v1 108/3/870    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by de Witte, M. A. Articles by Schumacher, T. N. M. Search for Related Content PubMed PubMed Citation Articles by de Witte, M. A. Articles by Schumacher, T. N. M. Related Collections Immunobiology Gene Therapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  GENE THERAPY Targeting self-antigens through allogeneic TCR gene transfer Moniek A. de Witte, Miriam Coccoris, Monika C. Wolkers, Marly D. van den Boom, Elly M. Mesman, Ji-Ying Song, Martin van der Valk, John B. A. G. Haanen, and Ton N. M. Schumacher From the Division of Immunology and Division of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam. Adoptive transfer of T-cell receptor (TCR) genes has been proposed as an attractive approach for immunotherapy in cases where the endogenous T-cell repertoire is insufficient. While there are promising data demonstrating the capacity of TCR-modified T cells to react to foreign antigen encounter, the feasibility of targeting tumor-associated self-antigens has not been addressed. Here we demonstrate that T-cell receptor gene transfer allows the induction of defined self-antigen–specific T-cell responses, even when the endogenous T-cell repertoire is nonreactive. Furthermore, we show that adoptive transfer of T-cell receptor genes can be used to induce strong antigen-specific T-cell responsiveness in partially MHC-mismatched hosts without detectable graft versus host disease. These results demonstrate the feasibility of using a collection of "off the shelf" T-cell receptor genes to target defined tumor-associated self-antigens and thereby form a clear incentive to test this immunotherapeutic approach in a clinical setting. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4 J. Immunol., June 15, 2008; 180(12): 8135 - 8145. [Abstract] [Full Text] [PDF] M. Coccoris, E. Swart, M. A. de Witte, J. W. J. van Heijst, J. B. A. G. Haanen, K. Schepers, and T. N. M. Schumacher Long-Term Functionality of TCR-Transduced T Cells In Vivo J. Immunol., May 15, 2008; 180(10): 6536 - 6543. [Abstract] [Full Text] [PDF] M. A. de Witte, A. Jorritsma, E. Swart, K. C. Straathof, K. de Punder, J. B. A. G. Haanen, C. M. Rooney, and T. N. M. Schumacher An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease J. Immunol., May 1, 2008; 180(9): 6365 - 6373. [Abstract] [Full Text] [PDF] A. Jorritsma, R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. N. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. M. Schumacher, et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma Blood, November 15, 2007; 110(10): 3564 - 3572. [Abstract] [Full Text] [PDF] M. Weinhold, D. Sommermeyer, W. Uckert, and T. Blankenstein Dual T Cell Receptor Expressing CD8+ T Cells with Tumor- and Self-Specificity Can Inhibit Tumor Growth without Causing Severe Autoimmunity J. Immunol., October 15, 2007; 179(8): 5534 - 5542. [Abstract] [Full Text] [PDF] I. G. Schuster, D. H. Busch, E. Eppinger, E. Kremmer, S. Milosevic, C. Hennard, C. Kuttler, J. W. Ellwart, B. Frankenberger, E. Nossner, et al. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies Blood, October 15, 2007; 110(8): 2931 - 2939. [Abstract] [Full Text] [PDF] C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. Toll-like Receptors in Tumor Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289. [Abstract] [Full Text] [PDF] M. H. M. Heemskerk, R. S. Hagedoorn, M. A. W. G. van der Hoorn, L. T. van der Veken, M. Hoogeboom, M. G. D. Kester, R. Willemze, and J. H. F. Falkenburg Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex Blood, January 1, 2007; 109(1): 235 - 243. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020